Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $79.6 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.